Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Renal pelvis and ureter cancer
Stage/Subtype:  regional transitional cell cancer of the renal pelvis and ureter
Country:  U.S.A.
Trial Type:  Treatment
Results 1-18 of 18 for your search:
Start Over
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-045, NCI-2014-02598, 152903, 2014-002009-40, NCT02256436
A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29294, NCI-2015-00200, 2014-003231-19, NCT02302807
Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHII-75, NCI-2009-00170, CDR0000492014, 7435, CCC-PHII-75, NCI-7435, NCT00365157
Everolimus With or Without Paclitaxel as First-Line Therapy in Treating Patients Advanced Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-147, NCI-2013-00308, 1008-13, 1011004329, NCT01215136
Dose Dense Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Muscle-Invasive Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-071, NCI-2012-00649, NCT01589094
Cabozantinib-S-Malate in Treating Patients with Metastatic Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0205, NCI-2013-01555, 120205, 12-C-0205J, P11900, 9236, NCT01688999
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GU12-160, NCI-2013-00935, NCT01780545
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0103-018, NCI-2014-02470, NCT02236195
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-052, NCI-2015-00614, 2014-002206-20, NCT02335424
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA209-275, NCI-2015-00650, NCT02387996
A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: B-701-U21, NCI-2015-00701, NCT02401542
Chemotherapy before Surgery in Treating Patients with High Grade Upper Urinary Tract Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA8141, NCI-2014-02267, NCT02412670
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B2151002, NCI-2013-01814, 2013-001390-24, NCT01920061
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 54828-101, NCI-2015-00611, NCT02393248
Cabozantinib-s-malate and Nivolumab with or without Ipilimumab in Treating Patients with Metastatic Genitourinary Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9681, NCI-2014-02379, 15-C-0160, NCT02496208
Start Over